Sorice, Gian Pio http://orcid.org/0000-0001-9489-1534
Cinti, Francesca http://orcid.org/0000-0001-5170-7055
Leccisotti, Lucia http://orcid.org/0000-0002-6000-2898
D’Amario, Domenico http://orcid.org/0000-0003-3774-8330
Lorusso, Margherita http://orcid.org/0000-0002-7867-2777
Guzzardi, Maria Angela http://orcid.org/0000-0001-9574-5088
Mezza, Teresa http://orcid.org/0000-0001-5407-9576
Cocchi, Camilla http://orcid.org/0000-0002-4355-6194
Capece, Umberto http://orcid.org/0000-0001-8048-8664
Ferraro, Pietro Manuel http://orcid.org/0000-0002-1379-022X
Crea, Filippo http://orcid.org/0000-0001-9404-8846
Giordano, Alessandro http://orcid.org/0000-0002-6978-0880
Iozzo, Patricia http://orcid.org/0000-0001-6443-7074
Giaccari, Andrea http://orcid.org/0000-0002-7462-7792
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
https://doi.org/10.1007/s13300-021-01083-1
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes
https://doi.org/10.1186/s12933-023-02091-0
Article History
Received: 9 April 2021
Accepted: 12 May 2021
First Online: 26 May 2021